Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data

• Published in: Frontiers in oncology Vol. 8; p. 450
• Main Authors: Giulietti, Matteo, Occhipinti, Giulia, Righetti, Alessandra, Bracci, Massimo, Conti, Alessandro, Ruzzo, Annamaria, Cerigioni, Elisabetta, Cacciamani, Tiziana, Principato, Giovanni, Piva, Francesco
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 12-10-2018
• Subjects: bladder cancer; gene expression; heterogeneity; Oncology; tumor biomarkers; WGCNA; tumor biomarkers; WGCNA; bladder cancer; gene expression; heterogeneity
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2018.00450

Bladder cancer is a very common malignancy. Although new treatment strategies have been developed, the identification of new therapeutic targets and reliable diagnostic/prognostic biomarkers for bladder cancer remains a priority. Generally, they are found among differentially expressed genes between patients and healthy subjects or among patients with different tumor stages. However, the classical approach includes processing these data taking into consideration only the expression of each single gene regardless of the expression of other genes. These complex gene interaction networks can be revealed by a recently developed systems biology approach called Weighted Gene Co-expression Network Analysis (WGCNA). It takes into account the expression of all genes assessed in an experiment in order to reveal the clusters of co-expressed genes (modules) that, very probably, are also co-regulated. If some genes are co-expressed in controls but not in pathological samples, it can be hypothesized that a regulatory mechanism was altered and that it could be the cause or the effect of the disease. Therefore, genes within these modules could play a role in cancer and thus be considered as potential therapeutic targets or diagnostic/prognostic biomarkers. Here, we have reviewed all the studies where WGCNA has been applied to gene expression data from bladder cancer patients. We have shown the importance of this new approach in identifying candidate biomarkers and therapeutic targets. They include both genes and miRNAs and some of them have already been identified in the literature to have a role in bladder cancer initiation, progression, metastasis, and patient survival.